According to a recent report, patients that recently took part in a Phase III clinical trial into mesothelioma treatment saw an improvement in survival rates. The Phase III trial involved administering the drugs Ranirnase and Doxorubicin to the patients that were taking part.

The clinical trial was carried out in Germany, and the people participating in the trial were patients with inoperable malignant mesothelioma, which is a form of cancer that results from long term or high level exposure to asbestos dust and fibers.

The median survival for patients that were treated with the combination drug treatment was 11.1 months, and this compared to 10.7 months for patients that were treated with doxorubicin plus placebo. A median survival of 10.5 months was seen in patients treated with other forms of chemotherapy, and this compared to 9 months for placebo.

It was noted that the drug Doxorubicin could cause side effects that included nausea and fatigue, but researchers stated that no adverse side effects were noted with Ranirnase.

Be Sociable, Share!